New imaging agent aims to predict cancer treatment success
NCT ID NCT06922825
First seen Feb 01, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This pilot study planned to test whether a radioactive imaging agent called 68Ga-FAPI-46 could help predict how well solid tumor patients respond to antibody-based therapy. Participants would have received an injection of the agent and undergone a PET/CT scan, with results compared to standard MRI or CT scans. The study was withdrawn before any participants were enrolled, so no conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-FAPI-46 (a radioactive imaging agent)
What this could lead to
If successful, this imaging method could help doctors predict which patients will respond to antibody-based cancer therapy, potentially guiding more personalized treatment.
What could go wrong
The trial was withdrawn before enrolling any participants, so no data was collected. It was a very early pilot study, and the imaging agent's predictive value remains unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.